Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
about
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.When and how can nephrologists treat hepatitis C virus infection in dialysis patients?A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good?Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data.Oncogenic Signaling Induced by HCV InfectionMolecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus InfectionStatins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysisIncreased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated DisadvantageThe osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replicationHepatocellular carcinoma presenting as spinal cord compression in Native Americans with controlled hepatitis C: two case reports
P2860
Q39197775-42B85843-A5DA-4AF4-95D5-75BE3353BAC8Q40054265-D617B268-2525-45A9-A15F-9C5A846826D8Q40252283-B7B70E13-5D84-4D95-930A-506215810529Q41921861-B7987F1E-FED2-44CC-8BE5-0D40BAC3AC97Q41934901-DEBF04D4-9209-4C3E-9357-8266A8A09E47Q45325612-DBF0490C-1526-4C87-9652-7C90F5EC3FA1Q45327946-37ADD2B2-AEBF-493C-B43B-75757FCE7741Q46644977-4FD08D42-2762-46AD-AB4B-C2934BB7D251Q47167981-85E2F7A4-FE0E-4BB8-B948-E51B07425E97Q55280981-5C446CBB-72FB-4882-BCF2-8E8FF917367EQ55657826-FCFF7B7F-5176-4035-B212-FF20B1528C68Q57050806-B7CCAC5F-B71D-4B23-8519-A13109A05C7DQ57067833-05343D79-5A7A-4636-A8BE-61EF5A9B523AQ58706537-E56235CA-EC13-4748-A7B0-17F2DE66B9A4Q58750606-C7759C13-D454-4811-B55B-FDAEAA5B4616Q58769353-5DC89B7E-A0C2-405A-A587-DBB950DC877AQ58795366-1E30EA56-2A9A-4C30-8BDD-5995168B0ABB
P2860
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@ast
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@en
type
label
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@ast
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@en
prefLabel
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@ast
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@en
P2093
P2860
P921
P1433
P1476
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
@en
P2093
Atsushi Ono
Frank Jühling
Thomas F Baumert
Yujin Hoshida
P2860
P2888
P356
10.1186/S12916-017-0815-7
P407
P5008
P577
2017-03-14T00:00:00Z
P6179
1083941586